Gennex Lab.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE509C01026
NSEID:
BSEID: 531739

INR

13.30

0.12 (0.91%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 1.73 lacs

{
  "main_header": {
    "sid": 930938,
    "name": "Gennex Lab.",
    "stock_name": "Gennex Lab.",
    "full_name": "Gennex Laboratories Ltd",
    "name_url": "stocks-analysis/gennex-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "13.30",
    "chg": 0.12,
    "chgp": "0.91%",
    "dir": 1,
    "prev_price": "13.18",
    "mcapval": "302.51 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531739,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE509C01026",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "23:49 PM",
    "bse_nse_vol": "1.73 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gennex-lab-930938-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gennex Laboratories Adjusts Valuation Grade Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-valuation-grade-upgraded-from-attractive-to-very-attractive-6-1572721",
        "imagepath": "",
        "date": "2025-03-24 08:00:48",
        "description": "Gennex Laboratories, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting a notable shift in its financial standing. The company currently reports a price-to-earnings (PE) ratio of 16.87 and an EV to EBITDA ratio of 10.89, indicating a competitive position within its industry. Additionally, Gennex boasts a PEG ratio of 0.40, suggesting a favorable growth outlook relative to its earnings.\n\nIn comparison to its peers, Gennex's financial metrics stand out. For instance, while Kopran holds an attractive valuation with a higher PE ratio of 19.63, Gennex's lower ratios may indicate a more appealing investment opportunity based on its current earnings performance. Other competitors, such as Shree Ganesh Remedies and Wanbury, exhibit significantly higher valuation metrics, which could suggest that Gennex is positioned more favorably in terms of value rel..."
      },
      {
        "title": "Gennex Laboratories Reports Strong Financial Growth Amid Market Challenges and Low Debt Levels",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-reports-87-05-increase-in-net-sales-amid-positive-financial-performance-1423647",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/GennexLaborator_mojoScore_682582.png",
        "date": "2025-03-18 08:17:12",
        "description": "Gennex Laboratories has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25. The company reported significant growth in net sales and profits, maintaining a low debt-to-equity ratio. However, it has faced challenges with return on equity and has underperformed compared to the broader market."
      },
      {
        "title": "Gennex Laboratories Reports Strong Financial Growth Amid Management Efficiency Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-downgraded-to-sell-amid-concerns-over-management-efficiency-and-roe-1400949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/GennexLaborator_mojoScore_681154.png",
        "date": "2025-03-17 10:35:21",
        "description": "Gennex Laboratories has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25, with significant growth in net sales and profits. However, challenges in management efficiency are noted, alongside a conservative debt approach. The company has shown consistent positive results over the past seven quarters."
      },
      {
        "title": "Gennex Laboratories Adjusts Valuation Grade Amidst Competitive Industry Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-valuation-grade-downgraded-from-very-attractive-to-attractive-1397745",
        "imagepath": "",
        "date": "2025-03-17 08:00:44",
        "description": "Gennex Laboratories, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting a shift in its financial standing. The company currently reports a price-to-earnings (PE) ratio of 16.61 and an EV to EBITDA ratio of 10.71, indicating its operational efficiency relative to its market valuation. Additionally, Gennex's PEG ratio stands at 0.40, suggesting a favorable growth outlook compared to its earnings.\n\nIn terms of return metrics, Gennex has shown resilience over the long term, with a remarkable 563.51% return over the past five years, significantly outperforming the Sensex, which recorded a 116.48% return in the same period. However, year-to-date performance shows a decline of 14.32%, contrasting with the Sensex's drop of 5.52%.\n\nWhen compared to its peers, Gennex maintains a competitive position, with several companies in the sector exhibiting higher..."
      },
      {
        "title": "Gennex Laboratories Hits 52-Week Low Amid Sustained Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-hits-52-week-low-amid-continued-stock-decline-and-poor-performance-1177368",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/GennexLaborator_priceRelatedfactors_563171.png",
        "date": "2025-03-03 14:21:07",
        "description": "Gennex Laboratories has reached a new 52-week low, continuing its downward trend and underperforming its sector. The stock has dropped 9.19% over the past three days and 30.34% over the past year, significantly lagging behind the broader market index, the Sensex."
      },
      {
        "title": "Gennex Laboratories Experiences Valuation Grade Change Amid Strong Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-valuation-grade-upgraded-from-attractive-to-very-attractive-1109253",
        "imagepath": "",
        "date": "2025-02-25 10:23:32",
        "description": "Gennex Laboratories, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting a more favorable assessment of its financial metrics. The company currently boasts a price-to-earnings (PE) ratio of 15.70 and an EV to EBITDA ratio of 10.08, indicating a competitive position within its industry. Additionally, Gennex's PEG ratio stands at a notable 0.38, suggesting efficient growth relative to its earnings.\n\nIn comparison to its peers, Gennex demonstrates a more attractive valuation profile. For instance, Shree Ganesh Remedies and Shukra Pharma exhibit significantly higher PE ratios of 32.65 and 108.77, respectively, while Gennex maintains a lower EV to EBIT ratio of 10.99 compared to the industry average. Furthermore, Gennex's return on capital employed (ROCE) is reported at 15.15%, which positions it favorably against competitors.\n\nDespite some fluctuati..."
      },
      {
        "title": "Gennex Laboratories Reports Strong Sales Growth Amidst Market Challenges and Low ROE",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-reports-87-05-increase-in-net-sales-amid-challenges-1107525",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/GennexLaborator_mojoScore_509703.png",
        "date": "2025-02-24 18:33:46",
        "description": "Gennex Laboratories has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25. The company reported an 87.05% increase in net sales, reaching Rs 40.01 crore, and a 48.58% rise in operating profit, while maintaining a low debt-to-equity ratio of 0.07 times."
      },
      {
        "title": "Gennex Laboratories Reports Strong Sales Growth Amid Management Efficiency Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-stock-downgraded-to-sell-amid-low-return-on-equity-1058929",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/GennexLaborator_mojoScore_475311.png",
        "date": "2025-02-19 19:03:52",
        "description": "Gennex Laboratories has recently experienced a change in evaluation, reflecting its strong financial performance for the quarter ending December 2024, marked by an 87.05% increase in net sales and a 48.58% rise in operating profit. However, challenges in management efficiency and a bearish stock classification persist."
      },
      {
        "title": "Gennex Laboratories Faces Significant Volatility Amid Broader Pharmaceuticals Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-hits-52-week-low-of-rs-11-62-amid-42-56-annual-decline-991243",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/GennexLaborator_priceRelatedfactors_418685.png",
        "date": "2025-02-12 10:07:00",
        "description": "Gennex Laboratories has faced significant volatility, reaching a new 52-week low and experiencing consecutive losses over the past four days. The stock has underperformed its sector and is trading below all major moving averages, reflecting ongoing challenges in the microcap pharmaceuticals market amid broader industry trends."
      }
    ],
    "total": 59,
    "sid": "930938",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/gennex-laboratories-930938"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "24-Mar-2025",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 20 2025 for Premier Fiscal Services Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.",
      "datetime": "24-Mar-2025",
      "details": "The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on March 20 2025 for Premier Fiscal Services Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
      "datetime": "20-Mar-2025",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 20 2025 for Premier Fiscal Services Pvt Ltd",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:10</strong> stock split, ex-date: 14 Dec 09",
          "dt": "2009-12-14",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:2</strong> rights issue, ex-date: 21 Jul 22",
          "dt": "2022-07-21",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Gennex Laboratories Adjusts Valuation Grade Amid Competitive Market Landscape

2025-03-24 08:00:48

Gennex Laboratories, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting a notable shift in its financial standing. The company currently reports a price-to-earnings (PE) ratio of 16.87 and an EV to EBITDA ratio of 10.89, indicating a competitive position within its industry. Additionally, Gennex boasts a PEG ratio of 0.40, suggesting a favorable growth outlook relative to its earnings. In comparison to its peers, Gennex's financial metrics stand out. For instance, while Kopran holds an attractive valuation with a higher PE ratio of 19.63, Gennex's lower ratios may indicate a more appealing investment opportunity based on its current earnings performance. Other competitors, such as Shree Ganesh Remedies and Wanbury, exhibit significantly higher valuation metrics, which could suggest that Gennex is positioned more favorably in terms of value rel...

Gennex Laboratories Reports Strong Financial Growth Amid Market Challenges and Low Debt Levels

2025-03-18 08:17:12

Gennex Laboratories has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25. The company reported significant growth in net sales and profits, maintaining a low debt-to-equity ratio. However, it has faced challenges with return on equity and has underperformed compared to the broader market.

Gennex Laboratories Reports Strong Financial Growth Amid Management Efficiency Challenges

2025-03-17 10:35:21

Gennex Laboratories has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25, with significant growth in net sales and profits. However, challenges in management efficiency are noted, alongside a conservative debt approach. The company has shown consistent positive results over the past seven quarters.

Gennex Laboratories Adjusts Valuation Grade Amidst Competitive Industry Landscape

2025-03-17 08:00:44

Gennex Laboratories, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting a shift in its financial standing. The company currently reports a price-to-earnings (PE) ratio of 16.61 and an EV to EBITDA ratio of 10.71, indicating its operational efficiency relative to its market valuation. Additionally, Gennex's PEG ratio stands at 0.40, suggesting a favorable growth outlook compared to its earnings. In terms of return metrics, Gennex has shown resilience over the long term, with a remarkable 563.51% return over the past five years, significantly outperforming the Sensex, which recorded a 116.48% return in the same period. However, year-to-date performance shows a decline of 14.32%, contrasting with the Sensex's drop of 5.52%. When compared to its peers, Gennex maintains a competitive position, with several companies in the sector exhibiting higher...

Gennex Laboratories Hits 52-Week Low Amid Sustained Market Underperformance

2025-03-03 14:21:07

Gennex Laboratories has reached a new 52-week low, continuing its downward trend and underperforming its sector. The stock has dropped 9.19% over the past three days and 30.34% over the past year, significantly lagging behind the broader market index, the Sensex.

Gennex Laboratories Experiences Valuation Grade Change Amid Strong Financial Metrics

2025-02-25 10:23:32

Gennex Laboratories, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting a more favorable assessment of its financial metrics. The company currently boasts a price-to-earnings (PE) ratio of 15.70 and an EV to EBITDA ratio of 10.08, indicating a competitive position within its industry. Additionally, Gennex's PEG ratio stands at a notable 0.38, suggesting efficient growth relative to its earnings. In comparison to its peers, Gennex demonstrates a more attractive valuation profile. For instance, Shree Ganesh Remedies and Shukra Pharma exhibit significantly higher PE ratios of 32.65 and 108.77, respectively, while Gennex maintains a lower EV to EBIT ratio of 10.99 compared to the industry average. Furthermore, Gennex's return on capital employed (ROCE) is reported at 15.15%, which positions it favorably against competitors. Despite some fluctuati...

Gennex Laboratories Reports Strong Sales Growth Amidst Market Challenges and Low ROE

2025-02-24 18:33:46

Gennex Laboratories has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25. The company reported an 87.05% increase in net sales, reaching Rs 40.01 crore, and a 48.58% rise in operating profit, while maintaining a low debt-to-equity ratio of 0.07 times.

Gennex Laboratories Reports Strong Sales Growth Amid Management Efficiency Challenges

2025-02-19 19:03:52

Gennex Laboratories has recently experienced a change in evaluation, reflecting its strong financial performance for the quarter ending December 2024, marked by an 87.05% increase in net sales and a 48.58% rise in operating profit. However, challenges in management efficiency and a bearish stock classification persist.

Gennex Laboratories Faces Significant Volatility Amid Broader Pharmaceuticals Sector Challenges

2025-02-12 10:07:00

Gennex Laboratories has faced significant volatility, reaching a new 52-week low and experiencing consecutive losses over the past four days. The stock has underperformed its sector and is trading below all major moving averages, reflecting ongoing challenges in the microcap pharmaceuticals market amid broader industry trends.

View All News

Announcement

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.

24-Mar-2025 | Source : BSE

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 20 2025 for Premier Fiscal Services Pvt Ltd

Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.

24-Mar-2025 | Source : BSE

The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on March 20 2025 for Premier Fiscal Services Pvt Ltd

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

20-Mar-2025 | Source : BSE

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 20 2025 for Premier Fiscal Services Pvt Ltd